BioVie Inc. BIVI
1.34 USD -0.39 (-22.54%)
At closeNov 4, 2026, 7:17 PM EST
1.32 -0.02 -1.49%
After hours · Nov 4, 7:17 PM ET
1.23 Day range 1.65
0.82 52-week range 3.79
- YTD
- +15.52%
- 1 year
- -12.42%
Analyst view
Price target (mean) 5.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current year | -4.41 | -4.41 – -4.41 | -7.30 | +39.6% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 1, 2024 | ThinkEquity | Initiated | — | Buy |
| Nov 30, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jul 18, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 17, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 17, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Feb 14, 2023 | Oppenheimer | Reiterated | — | Outperform |
| Sep 28, 2022 | EF Hutton | Maintained | — | Buy |
| Jul 22, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 17, 2022 | EF Hutton | Maintained | — | Buy |
| Mar 15, 2022 | Oppenheimer | Initiated | — | Outperform |
| Nov 30, 2021 | B. Riley Securities | Maintained | — | Buy |
| Jan 15, 2021 | B. Riley FBR | Initiated | — | Buy |